Table 1 Clinical Characteristics and Demographics of Glioma Patients (N = 53).
From: Glioma and temozolomide induced alterations in gut microbiome
Variable | N (%) |
|---|---|
Age group at diagnosis | |
18–54 | 26 (49) |
> 55 | 27 (51) |
Sex | |
Male | 34 (64) |
Female | 19 (36) |
Race/ethnicity | |
White/Caucasian | 26 (49) |
African American | 6 (12) |
Hispanic | 15 (28) |
Asian/Pacific Islander | 5 (9) |
Others | 1 (2) |
Pre-operative KPS | |
70 or more | 31 (58) |
< 70 | 22 (42) |
BMI | |
< 18.5 | 3 (6) |
18.5–24.9 | 12 (23) |
25–29.9 | 21 (40) |
30–34.9 | 9 (17) |
35–39.9 | 4 (7) |
> 40 | 4 (7) |
Tumor location* | |
Frontal | 24 (45) |
Parietal | 16 (30) |
Temporal | 25 (47) |
Occipital | 8 (15) |
Insular/Paralimbic | 21 (40) |
Brainstem, thalamus, and basal ganglia | 8 (15) |
Intraventricular | 4 (7) |
Butterfly | 4 (7) |
Multifocal | 4 (7) |
Diagnosis | |
Glioblastoma IDH-wild type | 40 (75) |
Glioblastoma IDH-mutant | 6 (12) |
Anaplastic astrocytoma IDH-wild type | 1 (2.5) |
Anaplastic oligodendroglioma IDH-mutant 1p19q co-deleted | 1 (2.5) |
Diffuse astrocytoma IDH-wild type | 2 (4) |
Diffuse astrocytoma IDH-mutant | 3 (6) |
Tumor volume (cc) ** | |
16.4 -113.3 | 14 (26) |
113.3—178.9 | 13 (24.67) |
178.9 -219.3 | 13 (24.67) |
219.3–374.4 | 13 (24.67) |
Radiological extent of resection (1st surgery) | |
GTR | 19 (36) |
NTR | 12 (23) |
STR | 18 (34) |
Biopsy | 4 (7) |
Temozolomide | |
Yes | 39 (74) |
No | 11 (20) |
Not available | 3 (6) |
Radiotherapy | |
Yes | 39 (74) |
No | 11 (20) |
Not available | 3 (6) |
Other treatments*** | |
Yes | 10 (19) |
No | 42 (81) |
Progression | |
Yes | 20 (38) |
No | 33 (62) |
Survival status | |
Death | 5 (9) |
Alive | 48 (91) |
